Investor Highlights

Pharmaxis CEO Gary Phillips details world-first clinical trial of treatment to prevent wound and burn scars

Pharmaxis Ltd CEO Gary Phillips speaks to Proactive's Andrew Scott soon after announcing they've entered a world-first clinical trial aiming to stop scars forming after trauma - particularly following burn injuries. Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials.

Watch the interview here.

Pharmaxis Announces World First Clinical Trial of Treatment to Prevent Wound and Burns Scars

A Pharmaxis (ASX:PXS) drug discovery has entered a world first clinical trial aiming to stop scars forming after trauma, particularly following burn injuries. Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials. Skin scarring after events such as accidents, surgery or burns place a substantial physical and psychological burden on patients. 

Professor Fiona Wood said, “It’s exciting for the research team to explore a novel path to reduce scarring and to be moving closer to that goal. Scar-less healing is the vision that has motivated our work over many decades.”

The Pharmaxis discovery, known as PXS-6302, has shown promising pre-clinical results in inhibiting the enzymes that play a critical role in the development of scar tissue.

Dr Kylie Sandy-Hodgetts, Senior Research Fellow at the School of Biomedical Sciences, UWA, said, “Current treatments aim to rectify the scar in the acute phase such as during wound healing and scar maturation through options such as compression therapy, silicone gel sheeting or when the scar is established by cryotherapy, scar revision or laser with limited outcomes at times.”

“This new compound may potentially avoid the need for invasive procedures such as further surgery or laser procedures.”

 The world-first human trial will determine the safety and tolerability of the product in healthy volunteers, which will lead to further trials in burns and surgical patients.

Read full media release - pdf

Chiesi USA Announces Commercial Launch of Pharmaxis’ Cystic Fibrosis Drug Bronchitol

Pharmaxis Ltd (ASX: PXS) today announced that Chiesi USA, Inc. (Chiesi), has launched Bronchitol® (mannitol), an add-on maintenance therapy to improve pulmonary function in cystic fibrosis (CF) patients aged 18 years and older in the United States. Bronchitol, developed by Pharmaxis, is the first dry powder inhaled mucoactive agent providing a compact, portable treatment option for CF patients.

Additionally, Chiesi has announced data from the Pharmaxis Phase 3 global clinical trial (CF303) evaluating the efficacy and safety of Bronchitol in adults with CF has been published online in the Journal of Cystic Fibrosis.

Pharmaxis has so far received a total of US$10 million in Bronchitol milestone payments from Chiesi triggered by FDA approval in October 2020 and the recent first shipment of stock to the USA.

Read full media release - pdf

Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced it has enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis.

The phase 1c/2a trial cleared by the FDA under the Investigational New Drug (IND) scheme aims to demonstrate that PXS-5505, the lead asset in Pharmaxis’ drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.

Pharmaxis has completed site initiation at several Australian and South Korean hospitals and the first patient has been enrolled. The dose escalation phase of the study that aims to select the optimum dose of PXS-5505.  This first phase, that will recruit up to 18 patients, is expected to conclude and report in 2H 2021 and will be followed by a six-month dose expansion phase (24 patients) to evaluate safety and efficacy. Sites in other countries including the USA will be added for the dose expansion phase.

Read full media release - pdf